About Us
Our family has always believed in the power of applying family principles to cultivate strong partnerships and achieve exceptional results.
We took on our first venture in 2003 with the founding of Nexus Pharmaceuticals, a U.S.-based specialty pharmaceutical manufacturer. Together, we scaled the company’s reach across global markets, including building a state-of-the-art production facility. In 2024, Nexus successfully divested that manufacturing facility to Eli Lilly, launching us into our next era.
Goldfinch was born directly from Nexus’ success. Fueled by a desire to create lasting value through a diversified private investment platform, each member brings their distinct expertise across operations, finance, business development, and technology, uniquely contributing to our growing portfolio of businesses and funds.